

---

**Research Article****Predictive Significance of Interleukin-6, Interleukin-8 and Tumor Necrosis Factor-Alpha in Paroxysmal Atrial Fibrillation****Mariya Negreva<sup>1\*</sup>, Krasimira Prodanova<sup>2</sup>, Svetoslav Georgiev<sup>3</sup>**<sup>1</sup>First Clinic of Cardiology, University Hospital of Varna, bul. Hr. Smirnenki 1, Varna, Bulgaria<sup>2</sup>Faculty of Applied Mathematics and Informatics, Technical University of Sofia, bul. Kl. Ohridski 8, Sofia, Bulgaria<sup>3</sup>First Clinic of Cardiology, University Hospital of Varna, bul. Hr. Smirnenki 1, Varna, Bulgaria**\*Corresponding author**

Mariya Negreva

Email: [mnegreva@abv.bg](mailto:mnegreva@abv.bg)

---

**Abstract:** Our previous studies presented significant increases in plasma concentrations of Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor-alpha (TNF- $\alpha$ ) as early as before the twenty-fourth hour after the clinical manifestation of paroxysmal atrial fibrillation (PAF). The early changes in pro-inflammatory cytokines give serious reasons to suppose that inflammatory process participates directly in the disease initiating mechanisms. In this sense, it is quite appropriate to seek in these changes a predictive value for PAF manifestation. IL-6, IL-8 and TNF- $\alpha$  were studied in 51 patients (26 men, 25 women; mean age  $59.84 \pm 1.60$  years) with PAF (time of the occurrence < 48 hours) and 52 controls (26 men, 26 women; mean age  $59.50 \pm 1.46$  years) matched by gender, age and comorbidities. In the present study we used a logistic regression model with a single explanatory variable and a multivariable logistic model to determine the prognostic value of the indicators. The logistic regression model with a single explanatory variable showed that IL-6, IL-8 and TNF- $\alpha$  were statistically significant indicators of the clinical manifestations of PAF ( $p < 0.001$ ;  $p = 0.045$ ;  $p = 0.014$ , respectively). With the increase in their values, the probability of developing the disease also increased ( $B_i = 0.33 > 0$ ;  $B_i = 0.34 > 0$ ;  $B_i = 0.44 > 0$ , respectively). The multivariate logistic model confirmed the results ( $p = 0.017$ ;  $p = 0.049$ ;  $p = 0.012$ , respectively). Plasma concentrations of IL-6, IL-8 and TNF- $\alpha$  provide prognostic information about the clinical manifestation of PAF. They could be used in the overall clinical risk assessment, which in turn would affect the prophylactic and therapeutic approach to the disease.

**Keywords:** Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- $\alpha$ ), paroxysmal atrial fibrillation

---

**INTRODUCTION**

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice, affecting >1% of the general population [1]. In Europe, more than 6 million people suffer from the disease and it is expected their number to double in the next 50 years, and in the US it is expected to affect 15.9 million [2, 3]. Data on the growing incidence give reasons to define AF as the "new epidemic" [4].

A series of studies demonstrated the negative impact of the arrhythmia on quality of life. It is a significant risk factor for thromboembolic events and is considered to cause one in five ischemic strokes [5]. AF increases cardiovascular morbidity and mortality, reduces physical capacity and cognitive function of patients [6, 7].

Paroxysmal atrial fibrillation (PAF) represents between 25% and 60% of all cases of AF and the risk of

stroke in it is not less than that in persistent and permanent AF [8]. The asymptomatic forms of the disease often remain undiagnosed, and therefore it is believed that about 30% of cryptogenic strokes are a consequence of PAF [9]. In this sense, introducing predictive for the expression of PAF biomarkers into clinical practice would contribute significantly to the assessment of embologenic risk and would be an important addition to the already well-established CHA<sub>2</sub>DS<sub>2</sub>-VASc score. Undoubtedly the predictive biomarkers will be also relevant in anti-relapse treatment.

Our previous studies present a significant increase in plasma concentrations of Interleukin-6 (IL-6), Interleukin-8 (IL-8) and Tumor Necrosis Factor-alpha (TNF- $\alpha$ ) in patients with PAF compared to controls with no episodes of the arrhythmia to date ( $p < 0.001$ ) (Table 1) [10, 11, 12]. The changes were established as early as before the twenty-fourth hour

after the clinical manifestation of paroxysmal atrial fibrillation (PAF). The patient and control group were free from accompanying diseases that affect the levels of studied cytokines. Precisely the formation of clear groups and the early changes give us a serious reason to assume that inflammation participates directly in the development of the arrhythmia. The idea of the involvement of the inflammatory process in the pathogenesis of AF is not new, but there is still uncertainty about its contribution to the clinical manifestation and course of the disease.

It is well known that the examined by us cytokines are one of the key regulatory molecules in the inflammatory response both on a local and systemic level. They are characterized by high sensitivity and fast dynamics in the presence of a stimulus [13, 14]. Therefore, cytokines allow for good monitoring of the inflammatory process. This was a prerequisite for our research.

**Table 1: Plasma concentrations of IL-6, IL-8 and TNF- $\alpha$  in the control subjects and patients with PAF**

	<b>Control subjects</b>	<b>Patients</b>	<b>P value</b>
<b>IL-6</b> (pg/mL)	14.21 $\pm$ 0.50	29.88 $\pm$ 1.68	p<0.001
<b>IL-8</b> (pg/mL)	32.18 $\pm$ 1.54	77.38 $\pm$ 3.78	p<0.001
<b>TNF-<math>\alpha</math></b> (pg/mL)	8.20 $\pm$ 0.29	15.06 $\pm$ 0.81	p<0.001

**PURPOSE**

The purpose of this study was to analyze the established by us changes in IL-6, IL-8 and TNF- $\alpha$  in patients with PAF in view of their predictive value for the manifestation of the disease.

Mandatory inclusion criteria were sustained recovery and maintenance of sinus rhythm after pharmacoverion with propafenone. In the absence of contraindications, the drug was administered in the prescribed for it scheme with a maximum duration of 24 hours [15, 16].

**MATERIALS AND METHODS**

**Study population**

Significant increases of plasma concentrations of IL-6, IL-8 and TNF- $\alpha$  were established in a study of 51 patients (26 men, 25 women; mean age 59.84 $\pm$ 1.60 years) with PAF (time of occurrence of the episodes <48 hours). They were selected from a total of 338 patients (see excl. criteria), hospitalized on grounds of a subjective sensation of "palpitations". The diagnosis "atrial fibrillation" was objectified on the basis of ECG immediately after the hospitalization of the patients.

52 participants (26 men, 26 women; mean age 59.50 $\pm$ 1.46 years) from a total of 169 screened without a history or ECG data for AF to date were selected for controls. The same exclusion criteria, used for the patient group, were applied to controls.

The study was conducted in the Intensive Coronary Care unit of First Cardiology Clinic at the University Hospital "St. Marina"- Varna for the period October 2010 – May 2012 after approval by the Ethics Committee of Research (№35/29.10.2010) at the same hospital and in accordance with the Declaration of Helsinki [17]. Participants were included in the study after previously signing the informed consent for participation.

Patients with PAF and the following diseases and conditions were excluded from the study:

**Sample collection and laboratory procedures**

Plasma concentrations of IL-6, IL-8 and TNF- $\alpha$  were tested immediately after hospitalization of the patients. Collection and storage of blood samples and the tests used are described in detail in our articles [10, 11, 12]. All procedures related to the study of the indicators were carried out in full compliance with the requirements of laboratory methods.

1. Cardiovascular diseases: coronary artery disease; chronic heart failure; uncontrolled hypertension; inflammatory diseases of the heart; congenital heart defects; moderate or severe acquired valvular diseases; cardiomyopathies.
2. Other diseases: kidney or liver failure; diseases of the central nervous system; inflammatory and/or infectious diseases in the past three months; neoplastic or autoimmune diseases; chronic lung disease; diseases of the endocrine system (with the exception of type 2 diabetes mellitus, non-insulin dependent, with a good control).
3. Intake of hormone replacement therapy or oral contraceptives, pregnancy, systemic administration of analgesics including NSAIDs; obesity with BMI>35.
4. Persistent rhythm disorder after administration of propafenone; restoration of sinus rhythm by electrical cardioversion (*only for patients*).

**Statistical analysis**

In the present study we used a logistic regression model with a single explanatory variable and a multivariable logistic model. This allowed us to seek predictors for the manifestation of PAF among the studied cytokines. Besides, this model made it possible to calculate the prognostic probability with which for a

certain value of the indicator it was expected for the complication to occur.

The mean values, standard error of the mean (SEM) and relative shares, cited by our previous studies, were presented using descriptive statistics. The testing of the equality hypothesis was done using Student's t-criterion.

Data analysis was performed with the specialized statistical analysis package STATISTICA, Version 10.0, 2010 (Stat Soft, Inc., Tulsa, OK, USA). The results were presented as mean ± SEM or n (%). Values of  $p < 0.05$  were considered statistically significant.

**RESULTS**

The logistic regression model with a single explanatory variable showed that plasma concentrations of IL-6, IL-8 and TNF- $\alpha$  were statistically significant

indicators of clinical manifestations of PAF ( $p < 0.001$ ;  $p=0.045$ ;  $p=0.014$ , respectively). With the increase in the values of each of these indicators, the probability of developing the disease also increased ( $B_1=0.33 > 0$ ;  $B_1=0.34 > 0$ ;  $B_1=0.44 > 0$ , respectively).


The equations of the fitted models were respectively:

$$\ln[p/(1-p)] = -6.08 + 0.33IL-6$$


$$\ln[p/(1-p)] = -15.51 + 0.34IL-8$$

$$\ln[p/(1-p)] = -4.59 + 0.44 TNF-\alpha,$$


Where  $p$  was the probability for the manifestation of PAF (Figure 1, 2, 3). They allow to determine the probability for the manifestation of the disease for each measured value of the indicator. The models we used correctly classified 77.88%, 85.44% and 72.82%, respectively, from the observed in our sample cases.



**Fig. 1: Probability distribution of IL-6 estimated using logistic model.**



**Fig. 2: Probability distribution of IL-8 estimated using logistic model.**



**Fig. 3: Probability distribution of TNF-α estimated using logistic model.**

The multivariate logistic model confirmed the predictive value of IL-6, IL-8 and TNF-α (p=0.017; p=0.049; p=0.012, respectively). The fitted equation showed that with the increase in the values of IL-6 ( $\hat{\beta}_1 = 0.21 > 0$ ), IL-8 ( $\hat{\beta}_2 = 0.31 > 0$ ) and TNF-α ( $\hat{\beta}_3 = 0.5 > 0$ ) there was an increase in the probability of the manifestation of the arrhythmia. The multivariate logistic model we created looked like this:

$$\ln[p/(1-p)] = -23.09 + 0.21IL-6 + 0.31IL-8 + 0.5TNF-\alpha$$

The statistical analysis in our previous studies showed that the patient group did not differ statistically from the control one in terms of number of participants in the group, mean age, gender structure, accompanying diseases, dyslipidemia and conducted treatment (*prior to hospitalization*). There was no significant difference between the two groups in terms of frequency of harmful habits and body mass index (BMI) (Table 2). The equalization of the two groups made it possible to compare them objectively and is a good prerequisite to seek predictive values of the established changes.

**Table 2: Clinical characteristics of patients with PAF and the control group**

	Patients with PAF	Control group	P value
<b>Number of participants</b>	51	52	0.89
<b>Age (years)</b>	59.84±1.60	59.50±1.46	0.87
<b>Men/Women</b>	26/25	26/26	1/ 0.93
<b>Accompanying diseases</b>			
Hypertension	37 (72.54%)	34 (65.38%)	0.44
Diabete mellitus type 2	3 (5.88%)	2 (3.84%)	0.62
<b>Dyslipidemia</b>	4 (7.84%)	3 (5.77%)	0.69
<b>Medicaments for Hypertension and Dyslipidemia</b>			
Beta blockers	19 (37.35%)	17 (32.69%)	0.62
ACE inhibitors	15 (29.41%)	14 (26.92%)	0.78
Sartans	11 (21.57%)	9 (17.31%)	0.58
Statins	4 (7.84%)	3 (5.77%)	0.69
Metformin	3 (5.88%)	2 (3.84%)	0.62
<b>Deleterious habits</b>			
Smoking	8 (15.69%)	7 (13.46%)	0.75
Drinking alcohol	7 (13.72%)	6 (11.53%)	0.74
<b>Body mass index (BMI) (kg/m<sup>2</sup>)</b>	23.85±0.46	24.95±0.45	0.09

## DISCUSSION

Inflammatory changes in AF are described as early as the 90s of the last century. The first results in this direction were presented by Frustaci *et al.* from histological examinations of the atrial myocardium [18]. Later, inflammatory activity was established also on a systemic level. Elevated plasma concentrations were measured in a number of inflammatory biomarkers such as chemokines, interleukine, acute phase proteins and others [19, 20]. Most often studied from them are CRP and IL-6, for which it is well known that they are the most unambiguous and definitive indicators of systemic inflammation. A series of studies also have proven that the values of inflammatory biomarkers increase with the accumulation of clinical risk factors for the development of AF [21, 22]. Inflammatory activity showed prognostic significance in patients with AF, and elevated levels are associated with increased mortality and thromboembolic events [23, 24, 25].

IL-6 is determined as the primary cytokine of the inflammatory cascade that is involved in both the acute phase and chronic inflammation [26]. Similarly, IL-8 is a key pro-inflammatory molecule and its levels are a good indicator of the activity of the inflammatory process [27]. TNF- $\alpha$  regulates the inflammatory response by triggering IL-6 and IL-1 production and stimulates metalloproteinase and neutrophil migration [28].

AF is often defined as an inflammatory disease. Therefore the predictive value of these key inflammatory molecules represents significant clinical interest in the AF population.

Several studies have shown that elevated serum levels of IL-6 are associated with the onset of AF after radiofrequency catheter ablation and electrical cardioversion [29, 30, 31]. Similar results were presented in patients after coronary artery by-pass operation. The increase in the values of the cytokine correlated with post-CABG AF occurrence [32, 33].

IL-6 and IL-8 are often placed into a single group of "inflammatory mediators" and are usually tested simultaneously to simplify the process. We cannot do this if we are looking for predictive significance. Clinical interest in plasma concentrations of IL-8 is significantly less compared to IL-6. The conducted studies are single. It has been established that the high serum levels of cytokines measured preoperatively could be used to identify patients prone to develop post-CABG AF [34]. In acute respiratory distress syndrome elevated levels of IL-8 are associated with the manifestation of new-onset AF [35].

Studies on TNF- $\alpha$  in AF showed that the values of cytokines were statistically significant for the

prediction of the clinical manifestation of the disease. A study with forty-four patients who underwent an initial pulmonary vein isolation show that the ablation responders had lower values of TNF- $\alpha$  [36]. The study by Vasiletz *et al.* also established a predictive value of the indicator in hypertensive patients [37]. TNF- $\alpha$ , studied before and after the first episode of persistent AF, proved to be a reliable early predictor of maintenance of sinus rhythm [38].

Our study confirms the results of previous studies in this field. The regression analysis we performed showed undoubtedly that the increased levels of proinflammatory cytokines IL-6, IL-8 and TNF- $\alpha$  are associated with increased probability of PAF. The equations of the fitted models allow us to determine with greater accuracy the probability of developing the disease in clinical practice.

Although the presented idea is not entirely new, the design of our study differs significantly. In this sense, it is right to emphasize that the presented by us patient population differs from the previously tested AF populations. It is characterized by "low burden of concomitant diseases". By eliminating a number of cardiovascular and heart diseases we can avoid their potential effects on the inflammatory status of the organism. The creation of pure groups allows us to present objectively the narrow relationship between the levels of IL-6, IL-8 and TNF- $\alpha$  and the rhythm disorder. Therefore, we believe that the results of the regression analysis are not an accidental finding, but reflect adequately the possibility for predicting the manifestation of PAF. The validation of laboratory indicators parameters with predictive values in clinical practice would influence the approach in the treatment of the rhythm disorder as well as its prognosis.

## CONCLUSION

Plasma concentrations of IL-6, IL-8 and TNF- $\alpha$  provide prognostic information on the clinical manifestation of PAF. They could be used in the overall clinical risk assessment, which in turn would affect the prophylactic and therapeutic approach to the disease.

## REFERENCES

1. Potpara TS, Lip GY; Lone atrial fibrillation: what is known and what is to come. *Int J Clin Pract.*, 2011;65(4):446-57.
2. Lip G, Caterina R, Savelieva I *et al*; ESC Committee for Practice Guidelines 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. *Eur Heart J.*, 2012; 33:2719-47.
3. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS; Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and

- implications on the projections for future prevalence. *Circulation*, 2006;114(2):119-25.
4. Lip GY, Kakar P, Watson T; Atrial fibrillation--the growing epidemic. *Heart*, 2007;93(5):542-3.
  5. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, et al; Outcome parameters for trials in atrial fibrillation: executive summary. *Eur Heart J.*, 2007;28(22):2803-17.
  6. Knecht S, Oeschläger C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt G, Berger K, Ringelstein EB, P Kirchhof, Werschling H; Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. *Eur Heart J.*, 2008;29(17):2125-32.
  7. Thrall G, Lane D, Carroll D, Lip GY; Quality of life in patients with atrial fibrillation: a systematic review. *Am J Med.*, 2006;119(5):448.e1-19.
  8. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL; Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. *JACC*, 2000;35(1):183-7.
  9. Khan M, Miller DJ; Detection of paroxysmal atrial fibrillation in stroke/TIA patients. *Stroke Res Treat.*, 2013;2013:840265.
  10. Negreva M, Georgiev S, Penev A; Cytokine Interleukin-6 in Patients with Paroxysmal Atrial Fibrillation. *IJPMR*, 2015;3(4):16-20.
  11. Negreva M, Georgiev S, Vitlianova K, Arabadzchieva D; Interleukin 8: Changes in Paroxysmal Atrial Fibrillation. *BJMMR*, 2015;10(8):1-7.
  12. Negreva M, Georgiev S, Penev A; Tumor Necrosis Factor – alpha in Clinical Manifestation of Paroxysmal atrial Fibrillation. *Varna Medical Forum*. Forthcoming, 2015.
  13. Commins SP, Borish L, Steinke JW; Immunologic messenger molecules: cytokines, interferons, and chemokines. *J Allergy Clin Immunol.*, 2010;125(2 Suppl 2):S53-72.
  14. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V; Evolutionary divergence and functions of the human interleukin (IL) gene family. *Hum Genomics*, 2010;5(1):30-55.
  15. Bellandi F, Cantini F, Pedone T, et al., Effectiveness of Intravenous Propafenone for Conversion of Recent-Onset Atrial Fibrillation: A Placebo-Controlled Study. *ClinCardiol.*, 1995;18:631-4.
  16. Bianconi L, Mennuni M; Comparison Between Propafenone and Digoxin Administered Intravenously to Patients With Acute Atrial Fibrillation. *Am J Cardiol*, 1998; 82:584-8.
  17. World Medical Association Declaration of Helsinki; Ethical principles for medical research involving human subjects. 59th WMA General Assembly. Seoul. 2008.
  18. Frustaci A, Caldarulo M, Buffon A, Bellocchi F, Fenici R, Melina D; Cardiac biopsy in patients with "primary" atrial fibrillation. Histologic evidence of occult myocardial diseases. *Chest.*, 1991;100:303-6.
  19. Patel P, Dokainish H, Tsai P, Lakkis N; Update on the association of inflammation and atrial fibrillation. *J CardiovascElectrophysiol*, 2010;21(9):1064-70.
  20. Friedrichs K, Klinke A, Baldus S; Inflammatory pathways underlying atrial fibrillation. *Trends Mol Med.*, 2011;17(10):556-63.
  21. Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Lappe DL, Bunch TJ; Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C - reactive protein incrementally and independently. *Pacing and clinical electrophysiology: PACE*, 2009;32:648-52.
  22. Ohara K, Inoue H, Nozawa T, Hirai T, Iwasa A, Okumura K, Lee JD, Shimizu A, Hayano M, Yano K; Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. *Int J Cardiol.*, 2008;126:316-21.
  23. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C - reactive protein in atrial fibrillation. *Am Heart J.*, 2004;148:462-6.
  24. Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A; Usefulness of high-sensitivity c-reactive protein to predict mortality in patients with atrial fibrillation (from the atherosclerosis risk in communities [aric] study). *Am J Cardiol.*, 2012;109:95-9
  25. Lip GY, Patel JV, Hughes E, Hart RG; High-sensitivity C - reactive protein and soluble cd40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors, stroke risk stratification schema, and prognosis. *Stroke*, 2007;38:1229-37.
  26. Barnes TC, Anderson ME, Moots RJ; The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis. *Int J Rheumatol.*, 2011;2011:721608.
  27. Apostolakis S, Vogiatzi K, Amanatidou V, Spandidos DA; Interleukin 8 and cardiovascular disease. *Cardiovasc Res.*, 2009;84(3):353-60.
  28. Guo Y, Lip GY, Apostolakis S; Inflammation in atrial fibrillation. *J Am CollCardiol.*, 2012;60(22):2263-70.
  29. Leftheriotis DI, Fountoulaki KT, Flevari PG, et al; The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. *Int J Cardiol.*, 2009 Jul 10;135(3):361-9.

30. Conway DS, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH; Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. *Scand J Clin Lab Invest*, 2009;69:425–32.
31. Henningsen KM, Nilsson B, Bruunsgaard H, Chen X, Pedersen BK, Svendsen JH; Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. *ScandCardiovasc J*, 2009;43:285–91.
32. Burzotta F, Blann AD, Balakrishnan B, et al; Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. *ThrombHaemost*, 2010;104:122–7.
33. Ucar H11, Tok M, Atalar E, Dogan OF, Oc M, Farsak B, Guvener M, Yilmaz M, Dogan R, Demircin M, Pasaoglu I; Predictive significance of plasma levels of interleukin-6 and high-sensitivity C-reactive protein in atrial fibrillation after coronary artery bypass surgery. *HeartSurg Forum.*, 2007;10(2):E131-5.
34. Mohamed A, El-Dien D; Preoperative serum levels of interleukin-6 and interleukin-8 as predictors of the development of postoperative atrial fibrillation among patients undergoing coronary artery bypass grafting surgery. *Egypt J CardiothoracAnesth.*, 2013;7(2):50-55.
35. Ambrus DB, Benjamin EJ, Bajwa EK, Hibbert KA, Walkey AJ; Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. *J Crit Care*, 2015. pii: S0883-9441(15)00345-7.
36. Kimura T, Takatsuki S, Inagawa K, Katsumata Y, Nishiyama T, Nishiyama N, Fukumoto K, Aizawa Y, Tanimoto Y, Tanimoto K, Fukuda K; Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. *Heart Lung Circ.*, 2014;23(7):636-43.
37. Vasilets LM, Agafonov AV, Khlynova OV, Ratanova EA, Grigoriadi NE, Krivaya AA, Trenogina KV; Prediction of Atrial Fibrillation According to Levels of Serum Markers of Inflammation during Arterial Hypertension. *Kazanskiy meditsinskiy zhurnal.*, 2012;4:642-6.
38. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, Venetsanou KS, Iliodromitis EK, Kremastinos DT; The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. *Int J Cardiol.*, 2009;135(3):361-9.